Daniel Meibom
Overview
Explore the profile of Daniel Meibom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abeje Y, Wieske L, Poongavanam V, Maassen S, Atilaw Y, Cromm P, et al.
J Med Chem
. 2024 Dec;
68(1):638-657.
PMID: 39693386
The discovery of cell permeable and orally bioavailable von Hippel-Lindau (VHL) proteolysis targeting chimeras (PROTACs) is challenging as their structures locates them at, or beyond, the outer limits of oral...
2.
Meibom D, Wasnaire P, Beyer K, Broehl A, Cancho-Grande Y, Elowe N, et al.
J Med Chem
. 2024 Feb;
67(4):2907-2940.
PMID: 38348661
The matrix metalloprotease ADAMTS7 has been identified by multiple genome-wide association studies as being involved in the development of coronary artery disease. Subsequent research revealed the proteolytic function of the...
3.
Roehrig S, Ackerstaff J, Jimenez Nunez E, Teller H, Ellerbrock P, Meier K, et al.
J Med Chem
. 2023 Sep;
66(17):12203-12224.
PMID: 37669040
Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it contributes to the development and progression of thrombosis but is thought to play only a minor role...
4.
Meibom D, Meyer J, von Buehler C, Collins K, Maassen S, Gericke K, et al.
J Med Chem
. 2023 Mar;
66(7):4659-4670.
PMID: 36932954
After acute myocardial infarction, early reperfusion is the most effective strategy for reducing cardiac damage and improving clinical outcome. However, restoring blood flow to the ischemic myocardium can paradoxically induce...
5.
Poongavanam V, Kolling F, Giese A, Goller A, Lehmann L, Meibom D, et al.
ACS Omega
. 2023 Feb;
8(6):5901-5916.
PMID: 36816707
Approaches for predicting proteolysis targeting chimera (PROTAC) cell permeability are of major interest to reduce resource-demanding synthesis and testing of low-permeable PROTACs. We report a comprehensive investigation of the scope...
6.
Meibom D, Micus S, Andreevski A, Anlauf S, Bogner P, von Buehler C, et al.
J Med Chem
. 2022 Dec;
65(24):16420-16431.
PMID: 36475653
Despite advances in the treatment of heart failure in recent years, options for patients are still limited and the disease is associated with considerable morbidity and mortality. Modulating cyclic guanosine...
7.
Poongavanam V, Atilaw Y, Siegel S, Giese A, Lehmann L, Meibom D, et al.
J Med Chem
. 2022 Sep;
65(19):13029-13040.
PMID: 36170570
Proteolysis-targeting chimeras (PROTACs) must be cell permeable to reach their target proteins. This is challenging as the bivalent structure of PROTACs puts them in chemical space at, or beyond, the...
8.
Atilaw Y, Poongavanam V, Nilsson C, Nguyen D, Giese A, Meibom D, et al.
ACS Med Chem Lett
. 2021 Jan;
12(1):107-114.
PMID: 33488971
Proteolysis targeting chimeras (PROTACs) induce intracellular degradation of target proteins. Their bifunctional structure puts degraders in a chemical space where ADME properties often complicate drug discovery. Herein we provide the...
9.
Beck H, Thaler T, Meibom D, Meininghaus M, Jorissen H, Dietz L, et al.
J Med Chem
. 2020 Sep;
63(20):11639-11662.
PMID: 32969660
Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chronic lung disease of unknown etiology. Despite the approved treatment options nintedanib and pirfenidone, the medical need for a safe and...
10.
Harter M, Kalthof B, Delbeck M, Lustig K, Gerisch M, Schulz S, et al.
Eur J Med Chem
. 2018 Dec;
163:763-778.
PMID: 30576906
The A adenosine receptor is a G protein-coupled receptor that belongs to the four member family of adenosine receptors: A, A, A, A. While adenosine-mediated A receptor signaling attenuates acute...